Factors associated with outcomes of severe acute necrotizing encephalopathy: A multicentre experience in Malaysia
Developmental Medicine & Child Neurology · 2023-09 · 65 (9) · 1256-1263
DOI: 10.1111/dmcn.15536 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Developmental Medicine & Child Neurology, online erschienen am 07.02.2023. Verfasst von Vanessa Wan Mun Lee und 10 weiteren Autor:innen. Beteiligte Einrichtung: Paediatric Neurology Unit, Hospital Tunku Azizah, Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Leukoencephalitis, Acute Hemorrhagic, Brain Diseases. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Ministry of Health, King's College London.
Abstract (Originalsprache)
This case series compared clinical variables and various combinations of immunotherapy received with outcomes of patients with severe acute necrotizing encephalopathy (ANE). We performed a retrospective review of clinical variables, immunotherapy received, and outcomes (based on the modified Rankin Scale) in Malaysia between February 2019 and January 2020. Twenty‐seven children (12 male), aged 7 months to 14 years (mean 4 years) at diagnosis were included. Of these, 23 had an ANE severity score of 5 to 9 out of 9 (high risk). Eleven patients received tocilizumab (four in combination with methylprednisolone [MTP], seven with MTP + intravenous immunoglobulin [IVIG]) and 16 did not (two received MTP alone, 14 received MTP + IVIG). Nine died. Among the survivors, six had good outcomes (modified Rankin Score 0–2) at 6 months follow‐up. All patients who received tocilizumab in combination with MTP + IVIG survived. Twenty children received first immunotherapy within 48 hours of admission. No significant association was found between the timing of first immunotherapy with outcomes. Those with brainstem dysfunction ( p = 0.016) were observed to have poorer outcomes. This study showed a trend towards better survival when those with severe ANE were treated with tocilizumab in combination with MTP + IVIG. However, larger studies will be needed to determine the effect of this regime on the long‐term outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Paediatric Neurology Unit, Hospital Tunku Azizah, Kuala Lumpur, Malaysia.
- Pediatric Neurology Unit, Hospital Pulau Pinang, Pulau Pinang, Malaysia.
- Pediatric Neurology Unit, Sabah Women and Children Hospital, Kota Kinabalu, Malaysia.
- Division of Pediatric Neurology, Department of Paediatrics, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia.
- Pediatric Unit, Faculty of Medicine, Universiti Teknologi Mara, Selangor Darul Ehsan, Malaysia.
- Paediatric Neurology Unit, Hospital Raja Perempuan Zainab II, Kota Bharu, Malaysia.
ORCID-Profile: Vanessa Wan Mun Lee
Förderung
- Ministry of Health
- King's College London
Zitieren
APA
Lee, V. W. M., Khoo, T. B., Teh, C. M., Heng, H. S., Li, L., Yusof, Y. L. M., Yahaya, N. A., Dharshini, S., Wong, S. W., Nickson, T., & ANE Malaysia Outcome Study Group (2023). Factors associated with outcomes of severe acute necrotizing encephalopathy: A multicentre experience in Malaysia. Developmental Medicine & Child Neurology, 65(9), 1256-1263. https://doi.org/10.1111/dmcn.15536
Vancouver
Lee VWM, Khoo TB, Teh CM, Heng HS, Li L, Yusof YLM, et al. Factors associated with outcomes of severe acute necrotizing encephalopathy: A multicentre experience in Malaysia. Developmental Medicine & Child Neurology. 2023;65(9):1256-1263. doi:10.1111/dmcn.15536
BibTeX
@article{Lee2023,
author = {Lee, Vanessa Wan Mun and Khoo, Teik Beng and Teh, Chee Ming and Heng, Hock Sin and Li, Limin and Yusof, Yusma Lyana Md and Yahaya, Nor Azni and Dharshini, Sangita and Wong, Sau Wei and Nickson, Tai and ANE Malaysia Outcome Study Group, ANE Malaysia Outcome Study Group},
title = {Factors associated with outcomes of severe acute necrotizing encephalopathy: A multicentre experience in Malaysia},
journal = {Developmental Medicine & Child Neurology},
year = {2023},
volume = {65},
number = {9},
pages = {1256--1263},
doi = {10.1111/dmcn.15536}
}
EUVIMED